| 前收盘价格 | 1.70 |
| 收盘价格 | 1.75 |
| 成交量 | 2,431,136 |
| 平均成交量 (3个月) | 1,214,996 |
| 市值 | 128,658,664 |
| 价格/销量 (P/S) | 225.55 |
| 股市价格/股市净资产 (P/B) | 2.38 |
| 52周波幅 | |
| 利润日期 | 7 May 2026 |
| 营业利益率 (TTM) | -13,194.49% |
| 稀释每股收益 (EPS TTM) | -0.930 |
| 季度收入增长率 (YOY) | -46.80% |
| 总债务/股东权益 (D/E MRQ) | 1.91% |
| 流动比率 (MRQ) | 6.22 |
| 营业现金流 (OCF TTM) | -42.75 M |
| 杠杆自由现金流 (LFCF TTM) | -25.76 M |
| 资产报酬率 (ROA TTM) | -41.00% |
| 股东权益报酬率 (ROE TTM) | -74.15% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看涨 | 混合的 |
| Biotechnology (全球的) | 看涨 | 混合的 | |
| 股票 | Cardiff Oncology, Inc. | 看跌 | 看跌 |
AIStockmoo 评分
-0.5
| 分析师共识 | 3.0 |
| 内部交易活动 | NA |
| 价格波动 | 0.5 |
| 技术平均移动指标 | -1.5 |
| 技术振荡指标 | -4.0 |
| 平均 | -0.50 |
|
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 5.64% |
| 机构持股比例 | 45.29% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Laurion Capital Management Lp | 31 Dec 2025 | 2,646,738 |
| Acorn Capital Advisors, Llc | 31 Dec 2025 | 1,962,084 |
| Blair William & Co/Il | 31 Dec 2025 | 1,948,847 |
| Flputnam Investment Management Co | 31 Dec 2025 | 595,328 |
| Northern Trust Corp | 31 Dec 2025 | 461,753 |
| Candriam S.C.A. | 31 Dec 2025 | 344,437 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 10.00 (HC Wainwright & Co., 423.56%) | 购买 |
| 中 | 8.00 (318.85%) | |
| 低 | 6.00 (Piper Sandler, 214.14%) | 购买 |
| 平均值 | 8.00 (318.85%) | |
| 总计 | 2 购买 | |
| 平均价格@调整类型 | 1.77 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Piper Sandler | 25 Feb 2026 | 6.00 (214.14%) | 购买 | 1.91 |
| HC Wainwright & Co. | 28 Jan 2026 | 10.00 (423.56%) | 购买 | 1.62 |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合